The study was a randomized, placebo-controlled comparison of the effects of daily treatment with fenofibrate 160 mg, ezetimibe-simvastatin 10/20 mg, ezetimibe-simvastatin 10/20 mg plus fenofibrate 160 ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ...

AMSTERDAM, THE NETHERLANDS — The investigational human monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab (Amgen) was safe and effective in patients with ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...

Please provide your email address to receive an email when new articles are posted on . Two small interfering RNA therapies lowered triglyceride levels in patients with mixed hyperlipidemia at 24 ...

An RNA interference therapy, targeting ANGPTL3 in the liver, drastically reduced fasting triglycerides in people with mixed hyperlipidemia, the ARCHES-2 trial showed. Used atop usual statins and other ...

Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia—elevations of triglycerides and cholesterol.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed ...